Primary percutaneous coronary intervention (PCI) is a not unusual remedy modality for patients with ST section elevation myocardial infarction (STEMI) [1]. However, no-reflow remains a tough hassle in the control of patients with STEMI undergoing number one PCI. It is widely recognized that angiographic no-reflow is strongly correlated with morbidity and mortality in acute STEMI. Rapid recovery of infarct-related arterial (IRA) float is related to improved ventricular performance and decrease mortality and morbidity amongst patients with myocardial infarction [2,3]. The pathophysiology of no-reflow has no longer but been completely explained, and its etiology appears to be multifactorial and very state-of-the-art [4].Several biomarkers are related to negative analysis in STEMI. Increased Mean platelet Volume (MPV) ranges were associated with poor scientific outcome in survivors of myocardial infarction [5,6]. C-reactive protein (CRP) is an acute section protein; numerous studies have shown that accelerated CRP might also have prognostic price in sufferers with acute coronary syndromes who're undergoing percutaneous coronary intervention [7,8,9].Growth Differentiation Factor-15 (GDF-15) is a cytokine acting as a marker of oxidative pressure; it plays a role in a couple of sicknesses which includes cardiovascular ailment, numerous cancers, renal failure, diabetes mellitus and inflammatory illnesses [10]. Most studies on GDF-15 in cardiovascular sickness have focused on coronary artery diseases, because this biomarker is strongly related to infarcted human heart [11,12]. In patients with non-ST-accelerated acute coronary syndrome, a high GDF-15 stage is a strong predictor of mortality and can be useful for decision making concerning an invasive remedy [13,14]